Connect with us


COVID-19: Limited Shipment Of Sputnik V Vaccine To Other Countries In December, Key Deliveries By January 2021, Says Russia

Dr Reddy’s Laboratories in India has collaborated with Russian Direct Investment Fund to conduct mid to late-stage human trials for the Sputnik V vaccine candidate in India

COVID-19: Limited Shipment Of Sputnik V Vaccine To Other Countries In December, Key Deliveries By January 2021, Says Russia
  • Russia’s COVID-19 vaccine showed 91.4% efficacy after 28 days of first dose
  • Preliminary data obtained after 42 days showed 95% efficacy of Sputnik V
  • The interim research data will be published by the Gamaleya Center team

New Delhi: Limited shipments of Sputnik V, the COVID-19 vaccine being developed by Russia will be done in December while key deliveries will be done in January 2021 to other countries, within the framework of existing contracts, Russian authorities said on Tuesday (November 24). “We are going to begin limited shipments for a number of countries in December but key delivery within the framework of the existing contract will be done in January if only those countries who recently provided their request– we will be shipping in March 2021,” said Kirill Dmitriev, CEO of Russian Direct Investment Fund (RDIF).

Also Read: Government Keeping A Close Eye On COVID-19 Vaccine Development: Prime Minister Narendra Modi

Kirill Dmitriev was responding to an online question on negotiations with drugs regulators of countries including India, Brazil, Singapore, Philippines and Korea.

It is important to know that we working with the regulatory agencies of all of the countries concerned to update them accordingly of all the data of Russian Federation clinical trials are very important for this data to be processed. We are in constant touch with regulatory authorities from over 50 countries on the data and results of our clinical trials preliminary and interim data has already been given to WHO and in a number of other international organizations, Kirill Dmitriev said.

Also Read: COVID-19: One Crore Frontline Healthcare Workers Identified To Received Vaccine In First Phase

“Hence, we working very closely with regulatory agencies from countries concerned and that since January we going to begin large volume of shipments and those countries that have been contracted recently the shipment will be by March 2021,” Kirill Dmitriev said at during a webinar held on Sputnik V COVID-19 vaccine.”

It may be noted that Dr Reddy’s Laboratories (DRL) in India has collaborated with RDIF to conduct mid to late-stage human trials for the Sputnik V vaccine candidate in India.

Earlier on Tuesday (November 24), the Gamaleya National Research Center for Epidemiology and Microbiology and RDIF declared results obtained during the second interim data analysis of the largest double-blind, randomized, placebo-controlled phase III clinical trials in Russia involving 40,000 volunteers.

It has shown a 91.4 per cent efficacy on day 28 after the first dose while preliminary data from volunteers obtained 42 days after the first dose(corresponds with 21 days after the second dose) indicates an efficacy of the vaccine above 95 per cent, stated press statement issued by RDIF.

Also Read: Russia Says Sputnik V Vaccine Over 95 Per Cent Effective Against COVID-19

“Evaluation of efficacy was carried out among volunteers (n = 18,794) 28 days after receiving the first dose (seven days after the second dose) of the vaccine or placebo upon reaching the second control point,” it said.

The interim research data will be published by the Gamaleya Center team in one of the leading international peer-reviewed medical journals.

There were no unexpected adverse events during the trials. Monitoring of the participants is ongoing, said the statement.

As per Russian scientists, the Sputnik V vaccine is based on a well-studied human adenoviral vector platform that has proven safe and effective with no long-term side effects in more than 250 clinical trials globally conducted during the past two decades – while the history of the use of human adenoviruses in vaccine development began in 1953.

More than 100,000 people have received approved and registered drugs based on human adenoviral vectors.

Also Read: Oxford COVID-19 Vaccine Candidate Shows 70 Per Cent Efficacy, Produces Strong Immune Response Among Elderlies

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

NDTV – Dettol Banega Swasth India campaign is an extension of the five-year-old Banega Swachh India initiative helmed by Campaign Ambassador Amitabh Bachchan. It aims to spread awareness about critical health issues facing the country. In wake of the current COVID-19 pandemic, the need for WASH (WaterSanitation and Hygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign highlights the importance of nutrition and healthcare for women and children to prevent maternal and child mortality, fight malnutrition, stunting, wasting, anaemia and disease prevention through vaccines. Importance of programmes like Public Distribution System (PDS), Mid-day Meal Scheme, POSHAN Abhiyan and the role of Aganwadis and ASHA workers are also covered. Only a Swachh or clean India where toilets are used and open defecation free (ODF) status achieved as part of the Swachh Bharat Abhiyan launched by Prime Minister Narendra Modi in 2014, can eradicate diseases like diahorrea and become a Swasth or healthy India. The campaign will continue to cover issues like air pollutionwaste managementplastic banmanual scavenging and sanitation workers and menstrual hygiene

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Folk Music For A Swasth India

Folk Music

Reckitt’s Commitment To A Better Future

India’s Unsung Heroes

Women’s Health

हिंदी में पड़े